| |
SPARCC SIJ BME
|
Erosion
|
Backfill
|
Fat metaplasia
|
Ankylosis
|
|---|
|
≥2 n = 128
|
>0 n = 58
|
0 n = 70
|
>0 n = 26
|
0 n = 102
|
>0 n = 14
|
0 n = 114
|
>0 n = 3
|
0 n = 125
|
|---|
|
<2 n = 55
|
>0 n = 6
|
0 n = 49
|
>0 n = 0
|
0 n = 55
|
>0 n = 1
|
0 n = 54
|
>0 n = 1
|
0 n = 54
|
|---|
|
Age, years
|
≥2
|
30.0 (6.1)
|
33.2 (8.0)
|
28.9 (6.9)
|
32.5 (7.3)
|
32.3 (7.6)
|
31.7 (7.3)
|
26.3 (1.2)
|
31.9 (7.4)
|
|
<2
|
35.3 (12.4)
|
32.4 (8.4)
|
─
|
32.7 (8.8)
|
40.0
|
32.6 (8.9)
|
25.0
|
32.9 (8.9)
|
|
Male, n (%)
|
≥2
|
51 (87.9)
|
34 (48.6)
|
21 (80.8)
|
64 (62.8)
|
12 (85.7)
|
73 (64.0)
|
3 (100)
|
82 (65.6)
|
|
<2
|
3 (50.0)
|
22 (44.9)
|
─
|
25 (45.5)
|
1 (100)
|
24 (44.4)
|
0
|
25 (46.3)
|
|
BMI, kg/m2
|
≥2
|
24.6 (3.5)
|
25.1 (4.5)
|
24.7 (3.8)
|
24.9 (4.2)
|
25.1 (3.1)
|
24.8 (4.2)
|
25.9 (4.9)
|
24.8 (4.1)
|
|
<2
|
26.7 (4.8)
|
25.3 (5.3)
|
─
|
25.4 (5.2)
|
30.1
|
25.4 (5.3)
|
17.3
|
25.6 (5.2)
|
|
Symptom duration, years
|
≥2
|
2.5 (2.3)
|
2.7 (1.5)
|
3.0 (2.9)
|
2.5 (1.5)
|
3.2 (1.7)
|
2.5 (1.9)
|
4.0 (1.2)
|
2.5 (1.9)
|
|
<2
|
2.4 (1.5)
|
2.0 (1.4)
|
─
|
2.0 (1.4)
|
0.3
|
2.0 (1.4)
|
4.0
|
2.0 (1.4)
|
|
HLA-B27 positive, n (%)
|
≥2
|
50 (86.2)
|
47 (67.1)
|
25 (96.2)
|
72 (70.6)
|
12 (85.7)
|
85 (74.6)
|
3 (100)
|
94 (75.2)
|
|
<2
|
5 (83.3)
|
30 (61.2)
|
─
|
35 (63.6)
|
1 (100)
|
34 (63.0)
|
1 (100)
|
34 (63.0)
|
|
Anterior uveitis, n (%)
|
≥2
|
5 (8.6)
|
8 (11.4)
|
1 (3.9)
|
12 (11.8)
|
2 (14.3)
|
11 (9.7)
|
1 (33.3)
|
12 (9.6)
|
|
<2
|
0
|
1 (2.0)
|
─
|
1 (1.8)
|
0
|
1 (1.9)
|
0
|
1 (1.9)
|
|
IBD, n (%)
|
≥2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
<2
|
0
|
1 (2.0)
|
─
|
1 (1.8)
|
0
|
1 (1.9)
|
0
|
1 (1.9)
|
|
PsO, n (%)
|
≥2
|
6 (10.3)
|
12 (17.1)
|
2 (7.7)
|
16 (15.7)
|
3 (21.4)
|
15 (13.2)
|
0
|
18 (14.4)
|
|
<2
|
0
|
5 (10.2)
|
─
|
5 (9.1)
|
0
|
3 (5.6)
|
0
|
5 (9.3)
|
|
PsO family history, n (%)
|
≥2
|
4 (6.9)
|
1 (1.4)
|
0
|
5 (4.9)
|
1 (7.1)
|
4 (3.5)
|
0
|
5 (4.0)
|
|
<2
|
0
|
3 (6.1)
|
─
|
3 (5.5)
|
0
|
3 (5.6)
|
0
|
3 (5.6)
|
|
ASDAS-CRP
|
≥2
|
3.0 (1.1)
|
3.1 (0.9)
|
3.2 (1.1)
|
3.0 (1.0)
|
2.7 (0.7)
|
3.1 (1.0)
|
3.1 (0.1)
|
3.1 (1.0)
|
|
<2
|
2.4 (1.3)
|
2.8 (0.8)
|
─
|
2.8 (0.9)
|
0.7
|
2.8 (0.8)
|
1.8
|
2.8 (0.9)
|
|
CRP, mg/l
|
≥2
|
7.6 (9.7)
|
7.7 (13.9)
|
8.6 (9.5)
|
7.4 (12.8)
|
4.0 (4.1)
|
8.1 (12.8)
|
2.8 (2.2)
|
7.7 (12.3)
|
|
<2
|
5.8 (10.0)
|
4.9 (7.0)
|
─
|
5.0 (7.2)
|
1.3
|
5.1 (7.3)
|
2.2
|
5.1 (7.3)
|
|
BASDAI, 0–10
|
≥2
|
5.6 (2.0)
|
6.4 (1.7)
|
5.9 (2.3)
|
6.1 (1.7)
|
5.4 (1.9)
|
6.1 (1.8)
|
6.8 (1.2)
|
6.0 (1.9)
|
|
<2
|
4.7 (2.5)
|
5.9 (1.6)
|
─
|
5.8 (1.7)
|
0.4
|
5.9 (1.6)
|
3.5
|
5.8 (1.7)
|
|
BASFI, 0–10 cm VAS
|
≥2
|
3.6 (2.6)
|
4.5 (2.5)
|
3.7 (2.8)
|
4.2 (2.5)
|
3.6 (2.0)
|
4.2 (2.6)
|
4.5 (0.7)
|
4.1 (2.6)
|
|
<2
|
3.0 (1.6)
|
3.9 (2.2)
|
─
|
3.8 (2.1)
|
0.5
|
3.8 (2.1)
|
2.9
|
3.8 (2.2)
|
|
BASMI, 0–10
|
≥2
|
1.1 (1.3)
|
1.3 (1.4)
|
1.1 (1.5)
|
1.2 (1.3)
|
0.9 (1.1)
|
1.3 (1.4)
|
1.3 (2.2)
|
1.2 (1.3)
|
|
<2
|
1.2 (1.0)
|
1.4 (1.3)
|
─
|
1.3 (1.3)
|
0
|
1.4 (1.3)
|
1.3
|
1.3 (1.3)
|
|
SPARCC spine score, 23-DVU, 0–414
|
≥2
|
7.5 (12.8)
|
4.0 (5.7)
|
9.1 (16.1)
|
4.6 (7.1)
|
5.6 (7.7)
|
5.5 (9.9)
|
11.7 (14.9)
|
5.4 (9.6)
|
|
<2
|
2.8 (4.2)
|
2.5 (3.9)
|
─
|
2.5 (3.9)
|
3.5
|
2.5 (3.9)
|
1.0
|
2.5 (3.9)
|
- Values are mean (standard deviation) unless stated otherwise. ASDAS-CRP Ankylosing Spondylitis Disease Activity Score based on C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, BME bone marrow edema, BMI body mass index, CRP C-reactive protein, DVU discovertebral units, HLA human leukocyte antigen, IBD inflammatory bowel disease, PsO psoriasis, SIJ sacroiliac joint, SPARCC Spondyloarthritis Research Consortium of Canada, VAS visual analog scale
